KR20170129906A - 유기 화합물 - Google Patents

유기 화합물 Download PDF

Info

Publication number
KR20170129906A
KR20170129906A KR1020177030305A KR20177030305A KR20170129906A KR 20170129906 A KR20170129906 A KR 20170129906A KR 1020177030305 A KR1020177030305 A KR 1020177030305A KR 20177030305 A KR20177030305 A KR 20177030305A KR 20170129906 A KR20170129906 A KR 20170129906A
Authority
KR
South Korea
Prior art keywords
disease
disorder
net
sert
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177030305A
Other languages
English (en)
Korean (ko)
Inventor
펑 리
준 자오
로렌스 피 웨노글
Original Assignee
인트라-셀룰라 써래피스, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인트라-셀룰라 써래피스, 인코퍼레이티드. filed Critical 인트라-셀룰라 써래피스, 인코퍼레이티드.
Publication of KR20170129906A publication Critical patent/KR20170129906A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020177030305A 2015-03-20 2016-03-18 유기 화합물 Withdrawn KR20170129906A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135915P 2015-03-20 2015-03-20
US62/135,915 2015-03-20
PCT/US2016/023198 WO2016154027A1 (en) 2015-03-20 2016-03-18 Organic compounds

Publications (1)

Publication Number Publication Date
KR20170129906A true KR20170129906A (ko) 2017-11-27

Family

ID=56977765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030305A Withdrawn KR20170129906A (ko) 2015-03-20 2016-03-18 유기 화합물

Country Status (13)

Country Link
US (1) US10188758B2 (enExample)
EP (1) EP3270920B1 (enExample)
JP (1) JP6726200B2 (enExample)
KR (1) KR20170129906A (enExample)
CN (1) CN107405339A (enExample)
AU (1) AU2016235483A1 (enExample)
BR (1) BR112017020135A2 (enExample)
CA (1) CA2978668A1 (enExample)
ES (1) ES2819833T3 (enExample)
IL (1) IL254320A0 (enExample)
MX (1) MX2017012022A (enExample)
RU (1) RU2017134796A (enExample)
WO (1) WO2016154027A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3339304A1 (en) 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
EP3339307A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
CN113195489A (zh) * 2018-11-02 2021-07-30 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物
EP3873902A1 (en) * 2018-11-02 2021-09-08 Esteve Pharmaceuticals, S.A. New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU2003287023A1 (en) * 2002-11-05 2004-06-03 Eli Lilly And Company 3-aryloxy/ thio-2, 3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
WO2007010082A1 (en) * 2005-07-15 2007-01-25 Fermion Oy Process for preparing a 3-aryloxy-3-arylpropylamine
CA2661187A1 (en) * 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
EP2161998B1 (en) * 2007-06-04 2015-09-02 Intra-Cellular Therapies, Inc. Pyridine derivatives as NET/SERT modulators
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US9352218B2 (en) 2009-04-21 2016-05-31 Nintendo Co., Ltd. Game apparatus and computer-readable storage medium

Also Published As

Publication number Publication date
IL254320A0 (en) 2017-11-30
EP3270920B1 (en) 2020-06-17
BR112017020135A2 (pt) 2018-05-29
EP3270920A4 (en) 2018-10-24
RU2017134796A (ru) 2019-04-04
ES2819833T3 (es) 2021-04-19
US20180099060A1 (en) 2018-04-12
WO2016154027A1 (en) 2016-09-29
MX2017012022A (es) 2018-01-30
JP2018508556A (ja) 2018-03-29
US10188758B2 (en) 2019-01-29
CN107405339A (zh) 2017-11-28
AU2016235483A1 (en) 2017-10-12
CA2978668A1 (en) 2016-09-29
EP3270920A1 (en) 2018-01-24
JP6726200B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
EP4114391B1 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
JP3346562B2 (ja) Ｐｃｐレセプター・リガンドおよびそれらを含む薬剤
CN101784273B (zh) (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法
JP4782003B2 (ja) ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体
EP0975595B1 (en) Analogs of cocaine
CN100513407C (zh) 三环δ阿片样物质调节剂
JP6977024B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法
KR20170129906A (ko) 유기 화합물
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
JP5384487B2 (ja) 新規方法
US10081600B2 (en) 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
CA2485537A1 (en) Novel compounds, their use and preparation
EP3720445A1 (en) Beta-2 selective adrenergic receptor agonists
CN101796027A (zh) N-哌啶-4-基甲基-酰胺衍生物及其作为单胺神经递质再摄取抑制剂的用途
JP6591431B2 (ja) 侵害受容処理並びに記憶障害及び認知異常の病態生理学的研究におけるプローブとして高度に選択的なシグマ受容体リガンド及び放射性リガンド
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
JP2006316064A (ja) ３（２ｈ）−ピリダジノン誘導体及びこれら化合物の使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171020

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination